Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
about
Amelioration of pathology by ELR-CXC chemokine antagonism in a swine model of airway endotoxin exposureα-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8Fibrogenesis: Mechanisms, Dynamics and Clinical ImplicationsInhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and functionNebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosisOvercoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectorsUnfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.Update in cystic fibrosis 2005Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion.Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections.Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity.Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis.Increased arginase activity in cystic fibrosis airways.Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection.Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
P2860
Q23915273-05895E70-A4A6-4802-809D-D2B907EDE0FFQ24633462-1499261B-0375-486B-8699-A191AD2A8B7CQ26782466-97033897-7694-4F78-BC25-856BE5137267Q26799406-22F4FF65-742D-407E-BA1F-45E62FB88481Q28305590-21C32C0C-8906-4B1F-BCD0-6386C4AE6E66Q30650955-242460EC-5B76-4FDA-A47D-88D707BDF77CQ33298018-9A41863E-C88D-4D85-908B-345B9484889EQ34058642-C2C15E06-F9A1-4910-B5D5-3A3C0199C483Q36457176-B9E17FA3-2ABA-45A4-B8B2-9F8AA9E5137AQ37308175-30D14ADA-AC37-4899-9BE8-85DA8D0B546BQ38522938-782541CC-211B-4568-888A-8062D70CDB90Q39258164-71E4A021-65AB-4CA9-94C7-98FE3B250653Q43244889-D866D313-2BB2-41E4-B205-4411F813141CQ46706389-44834136-9FC1-4FE1-A890-7A6164DB9CB2Q47662409-7F4F230B-ABDE-4BF2-81C4-47B9E766B85FQ58914917-CABED793-9FBC-4877-9E62-0C67C3C8BE4F
P2860
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@en
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@nl
type
label
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@en
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@nl
prefLabel
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@en
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@nl
P2093
P2860
P1476
Endothelial activation and increased heparan sulfate expression in cystic fibrosis.
@en
P2093
Janis K Shute
John Wilson
Nicola Solic
Susan J Wilson
P2860
P304
P356
10.1164/RCCM.200409-1207OC
P407
P577
2005-06-23T00:00:00Z